PARP Inhibitors Could Mean "A Whole New Direction for Cancer"

June 25, 2009

NBC Nightly News

Susan Domchek, MD, as associate professor in the division of Hematology/Oncology and director of the Cancer Risk Evaluation program in the Abramson Cancer Center, is quoted in an NBC Nightly News story about a new class of drugs called PARP inhibitors, which are proving successful in the treatment of patients who carry cancers of the breast, ovaries, and prostate that are linked to the BRCA 1 and BRCA 2 mutations. The drugs work by blocking a protein that prevents cancer cells - especially those that are deficient in BRCA - from repairing themselves. Domchek's patient, Patricia Buckles, also appears in the segment, discussing how her tumors have shrunk since she began taking the drugs and the minimal side effects she has experienced... View Segment

To learn more about clinical trials at Penn's Abramson Cancer Center click here or call 1-800-789-PENN (7366).